Biology of Blood and Marrow Transplantation
Volume 15, Issue 12 , Pages 1513-1522 , December 2009

Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation

  • Yang Wang

      Affiliations

    • Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • Both of these authors contributed equally to this work.
    • ,
  • Dan Li

      Affiliations

    • Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • Both of these authors contributed equally to this work.
    • ,
  • Dan Jones

      Affiliations

    • Department of Hematopathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Roland Bassett

      Affiliations

    • Department of Biostatistics and Applied Mathematics, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • George E. Sale

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Jahan Khalili

      Affiliations

    • Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Krishna V. Komanduri

      Affiliations

    • Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Daniel R. Couriel

      Affiliations

    • Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Richard E. Champlin

      Affiliations

    • Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Jeffrey J. Molldrem

      Affiliations

    • Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Qing Ma

      Affiliations

    • Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • Corresponding Author InformationCorrespondence and reprint requests: Qing Ma, Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Unit 900, 1515 Holcombe Boulevard, Houston, TX 77030.

Received 16 November 2008 ,Accepted 18 August 2009.

References 

  1. Sale GE, Shulman HM, Hackman RC. Pathology of hematopoietic cell transplantation. In:  Blume KG,  Forman SJ,  Appelbaum FR editor. Thomas's Hematopoietic Cell Transplantation. Boston: Blackwell Scientific; 2004;p. 286–299
  2. Antin JH, Deeg HJ. Clinical spectrum of acute graft-vs-host disease. In:  Ferrara JLM,  Cooke KR,  Deeg HJ editor. Graft-vs-Host-Disease. New York: Marcel Dekker; 2005;p. 369–382
  3. Ferrara JLM, Cooke KR, Teshima T. The pathophysiology of graft-vs-host disease. In:  Ferrara JLM,  Cooke KR,  Deeg HJ editor. Graft-vs-Host-Disease. New York: Marcel Dekker; 2005;p. 1–34
  4. Korngold R, Friedman TM. Murine models for graft-versus-host disease. In:  Blume KG,  Forman SJ,  Appelbaum FR editor. Thomas's Hematopoietic Cell Transplantation. Boston: Blackwell Scientific; 2004;p. 353–368
  5. Blazar BR, Korngold R, Vallera DA. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev. 1997;57:79–109
  6. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301–314
  7. Dustin ML. Coordination of T cell activation and migration through formation of the immunological synapse. Ann NY Acad Sci. 2003;987:51–59
  8. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60–66
  9. Gahmberg CG, Tolvanen M, Kotovuori P. Leukocyte adhesion–structure and function of human leukocyte beta2-integrins and their cellular ligands. Eur J Biochem. 1997;245:215–232
  10. Diamond MS, Springer TA. The dynamic regulation of integrin adhesiveness. Curr Biol. 1994;4:506–517
  11. Ding ZM, Babensee JE, Simon SI, et al. Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. J Immunol. 1999;163:5029–5038
  12. Schmits R, Kundig TM, Baker DM, et al. LFA-1–deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J Exp Med. 1996;183:1415–1426
  13. Berlin-Rufenach C, Otto F, Mathies M, et al. Lymphocyte migration in lymphocyte function-associated antigen (LFA)-1–deficient mice. J Exp Med. 1999;189:1467–1478
  14. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant. 2006;6:27–36
  15. Kootstra CJ, Van Der Giezen DM, Van Krieken JH, et al. Effective treatment of experimental lupus nephritis by combined administration of anti-CD11a and anti-CD54 antibodies. Clin Exp Immunol. 1997;108:324–332
  16. van Kooyk Y, de Vries-van der Zwan A, de Waal LP, et al. Efficiency of antibodies directed against adhesion molecules to prolong skin graft survival in mice. Transplant Proc. 1994;26:401–403
  17. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. Co-blockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex–disparate donor grafts. Blood. 1995;85:2607–2618
  18. Harning R, Pelletier J, Lubbe K, et al. Reduction in the severity of graft-versus-host disease and increased survival in allogenic mice by treatment with monoclonal antibodies to cell adhesion antigens LFA-1 alpha and MALA-2. Transplantation. 1991;52:842–845
  19. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004–2013
  20. Carman CV, Springer TA. Integrin avidity regulation: are changes in affinity and conformation underemphasized?. Curr Opin Cell Biol. 2003;15:547–556
  21. Hogg N, Smith A, McDowall A, et al. How T cells use LFA-1 to attach and migrate. Immunol Lett. 2004;92:51–54
  22. Hynes RO. Structural biology: changing partners. Science. 2003;300:755–756
  23. Shimaoka M, Takagi J, Springer TA. Conformational regulation of integrin structure and function. Annu Rev Biophys Biomol Struct. 2002;31:485–516
  24. Legge GB, Morris GM, Sanner MF, et al. Model of the alphaLbeta2 integrin I-domain/ICAM-1 DI interface suggests that subtle changes in loop orientation determine ligand specificity. Proteins. 2002;48:151–160
  25. Lu C, Shimaoka M, Zang Q, et al. Locking in alternate conformations of the integrin alphaLbeta2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc Natl Acad Sci USA. 2001;98:2393–2398
  26. Shimaoka M, Lu C, Palframan RT, et al. Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin alphaL I domains with high affinity and antagonist activity in vivo. Proc Natl Acad Sci USA. 2001;98:6009–6014
  27. Ma Q, Shimaoka M, Lu C, et al. Activation-induced conformational changes in the I domain region of lymphocyte function-associated antigen 1. J Biol Chem. 2002;277:10638–10641
  28. Wang Y, Li D, Nurieva R, et al. LFA-1 affinity regulation is necessary for the activation and proliferation of naïve T cells. J Biol Chem. 2009;284:12645–12653
  29. Gadek TR, Burdick DJ, McDowell RS, et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science. 2002;295:1086–1089
  30. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci. 2002;23:482–486
  31. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687–692
  32. Zeiser R, Youssef S, Baker J, et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007;110:4588–4598
  33. Pugashetti R, Koo J. Efalizumab discontinuation: a practical strategy. J Dermatol Treat. 2009;20:132–136
  34. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106:1113–1122
  35. Hori A, Kanda Y, Goyama S, et al. Japan Hematology and Oncology Clinical Study Group. A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation. 2005;79:372–374
  36. Giblin PA, Lemieux RM. LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1–based therapeutics. Curr Pharm Des. 2006;12:2771–2795
  37. Frenette PS. Locking a leukocyte integrin with statins. N Engl J Med. 2001;345:1419–1421
  38. Duggan DE, Chen IW, Bayne WF, et al. The physiological disposition of lovastatin. Drug Metab Dispos. 1989;17:166–173

 Financial disclosure: See Acknowledgments on page 1521.

PII: S1083-8791(09)00392-9

doi: 10.1016/j.bbmt.2009.08.013

Biology of Blood and Marrow Transplantation
Volume 15, Issue 12 , Pages 1513-1522 , December 2009

Article Tools

* Image Usage & Resolution